DeCure for Familial cold autoinflammatory syndrome 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for familial cold autoinflammatory syndrome 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFamilial cold autoinflammatory syndrome 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for familial cold autoinflammatory syndrome 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Familial cold autoinflammatory syndrome 2 is a cryopyrin-associated periodic syndrome, one of a group of hereditary autoinflammatory diseases defined by recurrent, often unprovoked attacks of systemic inflammation linked to dysregulation of the innate immune system. The 2014 and 2020 reviews describe these disorders as Mendelian conditions that activate NOD-like receptors and inflammasome products, especially interleukin 1, but neither review provides any data on treatment outcomes, survival, or response rates for familial cold autoinflammatory syndrome 2 specifically. The 2021 case report notes that familial cold autoinflammatory syndrome presents with episodic fever, skin rash, and joint pain after cold exposure, and that concurrent autoimmune pathologies such as rheumatoid arthritis or amyloidosis can occur. The authors found seven previously reported cases of familial cold autoinflammatory syndrome with amyloidosis and five cases with rheumatoid arthritis, then added one more dual-diagnosis case. No numbers on treatment response or disease course are given for any of these cases.
The abstracts contain no controlled trials, no survival statistics, and no response rates for any drug in familial cold autoinflammatory syndrome 2. The 2014 and 2020 reviews mention interleukin 1 as a key product of inflammasome activation in autoinflammatory diseases generally, but they do not report outcomes of interleukin 1 blockade in this specific syndrome. The 2021 case report describes only the diagnostic challenge of overlapping symptoms and the tally of prior published cases, not the results of any therapeutic intervention.
What is missing is any prospective trial data, any randomised or even large observational study that reports objective outcomes for familial cold autoinflammatory syndrome 2 patients treated with any agent. There is no evidence on which to judge whether existing treatments alter the natural history of the syndrome, and no stratification by genotype or comorbidity. Without funding for a dedicated trial and systematic collection of outcome measures, the evidence remains limited to case counts and general reviews.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Modern Research in Inflammation · 2014 · 17 citations · open access
Autoinflammatory diseases in childhood
AbstractAutoinflammatory diseases are defined as recurrent attacks of systemic inflammation that are often unprovoked (or triggered by a minor event) related to a lack of adequate regulation of the innate immune system. Within the past decade, the list of autoinflammatory diseases has included cryopyrin-associated periodic syndromes, familial Mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome, hereditary pyogenic disorders, pediatric granulomatous autoinflammatory diseases, idiopathic febrile syndromes (systemic-onset juvenile idiopathic arthritis, PFAPA syndrome), complement dysregulation syndromes and Behet's disease. The hereditary autoinflammatory diseases are a group of Mendelian disorders characterized by seemingly unprovoked fever and localized inflammation. Autoinflammatory diseases can activate NOD-like receptors and inflammasome products including especially interleukin 1. In this review, it focuses on how recent advances have impacted hereditary autoinflammatory diseases.
Clinical pharmacology and therapy · 2020 · 4 citations · open access
Autoinflammatory diseases
AbstractAutoinflammatory diseases are a group of disorders caused by a dysregulation of the innate immune system. Unlike autoimmune diseases, they are not associated with changes in humoral or cellular immunity. The authors review the current classification, clinical manifestations and treatment of various systemic autoinflammatory diseases, including cryopirinassociated periodic syndrome, familial Mediterranean fever, HIDS, and TRAPS.
Baylor University Medical Center Proceedings · 2021 · 2 citations · open access
Familial cold autoinflammatory syndrome with rheumatoid arthritis
AbstractFamilial cold autoinflammatory syndrome (FCAS) is a cryopyrin-associated periodic syndrome that presents with episodic fever, skin rash, and joint pain after exposure to cold temperatures. Although the diagnosis is often singular, there are several instances of concurrent underlying autoimmune pathologies with either rheumatoid arthritis (RA) or amyloidosis. Because symptoms of the two entities overlap, it can be difficult to address a potential dual diagnosis of FCAS and an autoimmune disorder. We found seven previously reported cases of FCAS and amyloidosis and five cases of FCAS and RA and present another case of an FCAS-RA dual diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
